The Canadian pharmacy services firm reports stable adjusted EBITDA and cash flow despite flat earnings in the quarter.
CareRx reported a GAAP EPS of C$0.01 for Q2 2026, matching revenue of C$93.6 million. The results reflect steady performance amid consistent operational metrics.
Adjusted EBITDA held at C$8.0 million, unchanged from Q2 2025. Cash from operations also remained stable at C$3.7 million, compared to C$3.8 million in the same period last year.
The company did not disclose immediate market reactions in the release.